Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2636

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2636
---
 identity and possibly leading to market
confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or
trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we are unable to establish name
recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.
We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines
for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees
may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect
our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may
be ineffective and could result in substantial costs and diversion of resources and could adversely affect our competitive position,
business, financial condition, results of operations and prospects.

105

Risks
Related to Managing Our Business and Operations

Our
internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.

Our
internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such
a material system failure, accident or security breach could result in a disruption of our development programs and our business operations,
whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical
trial data from an of our clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs
to recover or reproduce the data. Additionally, during the COVID-19 pandemic, there were a number of security breaches relating
to companies providing or developing treatments or vaccines related to COVID-19. To the extent that any disruption or security breach
were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates
could be delayed.

We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of